In today’s recent session, 0.47 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) have been traded, and its beta is 1.80. Most recently the company’s share price was $1.81, and it changed around -$0.1 or -5.24% from the last close, which brings the market valuation of the company to $274.52M. HRTX at last check was trading at a discount to its 52-week high of $3.93, offering almost -117.13% off that amount. The share price’s 52-week low was $0.50, which indicates that the recent value has risen by an impressive 72.38% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 1.33 million shares, with the 3-month average coming to 2.05 million.
Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX has been showing red trend so far today with a performance of -5.24% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.9950 on recent trading dayincreased the stock’s daily price by 9.27%. The company’s shares are currently up 6.47% year-to-date, but still up 1.69% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is -9.05% down in the 30-day period. We can see from the shorts that 30.64 million shares have been sold at a short interest cover period of 15.54 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 74.14% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $9.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Heron Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -21.98 percent over the past six months and at a 86.25% annual growth rate that is well above the industry average of 17.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%. Heron Therapeutics Inc earnings are expected to increase by 84.19% in 2024, but the outlook is positive 47.50% per year for the next five years.
HRTX Dividends
Heron Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-12.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.69% of Heron Therapeutics Inc shares, and 86.73% of them are in the hands of institutional investors. The stock currently has a share float of 87.33%. Heron Therapeutics Inc stock is held by 227.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 17.6678% of the shares, which is about 26.71 million shares worth $93.5 million.
VANGUARD GROUP INC, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
